Clinical trials: Diabete Type 2
Diabetic Kidney Disease
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease
- Trial name
- NCT01752985
- Testing
- BMS-813160
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 319 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2
A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02390050
- Testing
- Bexagliflozin tablets
- Where
- 50 sites in United States, Japan
- Volunteers
- 292 people
- Sponsor
- Theracos
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
The objective of the randomised part of the study is to investigate the efficacy and safety of BI 1356 plus metformin compared to BI 1356 or metformin alone given for 24 weeks to drug naive or previously treated (4 weeks…
- Trial name
- NCT00798161
- Testing
- BI 1356, BI 1356 + metformin, Metformin
- Where
- 138 sites in Canada, Croatia and 12 more
- Volunteers
- 857 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
To Bathe or Not to Bathe
Type 2 diabetes mellitus (T2DM) is characterised by chronic high blood sugar concentration (hyperglycaemia) and insulin resistance leading to a reduction in insulin sensitivity.
- Trial name
- NCT03798717
- Testing
- Heating
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Portsmouth
Diabetes Mellitus, Type 2, Hypertension
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of…
- Trial name
- NCT01939496
- Testing
- Canagliflozin
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- Janssen Scientific Affairs, LLC
Diabetes Mellitus, Type 2, Insulin Resistance
The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly
Like most endocrine axes, the entero-insular axis is expected to go through an age-related physiological deterioration, what might contribute to special features of the elderly onset type 2 diabetes in comparison to middle-age.
- Trial name
- NCT00843479
- Where
- Brazil
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil
Diabetes Mellitus, Type 2
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
This study will investigate and compare the pharmacokinetics of a single 25-mg dose of MK-3102 in participants with moderate hepatic impairment and matched healthy participants.
- Trial name
- NCT01767688
- Testing
- MK-3102
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30…
- Trial name
- NCT01183013
- Testing
- Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg
- Where
- 132 sites in United States, Estonia and 4 more
- Volunteers
- 936 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at Month 6, Week 26) in participants with type 2 diabetes mellitus…
- Trial name
- EDITION III (NCT01676220)
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 217 sites in United States, Bulgaria and 14 more
- Volunteers
- 878 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin
- Trial name
- NCT01517373
- Testing
- PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg
- Where
- 53 sites in United States, Bulgaria and 5 more
- Volunteers
- 304 people
- Sponsor
- Pfizer
Type 2 Diabetes
Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
Background: Pioglitazone has been shown to have potent anti-inflammatory as well anti-atherosclerotic effects. However, the mechanisms by which pioglitazone exerts these effects are not clear.
- Trial name
- PIO-TACE (NCT01223196)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes
A Single Supplement of a Standardised Bilberry Extract Modifies Glycaemic Response
Dietary strategies for alleviating health complications associated with type 2 diabetes (T2D) are being pursued as alternatives to pharmaceutical interventions.
- Trial name
- NCT01245270
- Testing
- Bilberry capsule first, then control cap, Control capsule first then bilberry cap
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- University of Aberdeen
Type 2 Diabetes Mellitus
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
The purpose of the study is to compare the pharmacodynamic effects of lixisenatide (AVE0010), in comparison to liraglutide, as an add-on treatment to metformin, over a period of 4 weeks of treatment.
- Trial name
- NCT01175473
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Liraglutide
- Where
- 7 sites in Germany
- Volunteers
- 148 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients
In this project the investigators examined the impact of diabetes self-management education using text messaging on increasing awareness of CVD risk perception, dietary intake, physical activity, and diabetes self-management…
- Trial name
- NCT03039569
- Testing
- Text messaging
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of Nebraska Lincoln
Diabetes Mellitus, Type 2
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
This is a multi-center, open-label, parallel-group, randomized controlled study in subjects with type 2 diabetes using multiple daily injection (MDI) insulin therapy.
- Trial name
- NCT04090242
- Testing
- BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- Becton, Dickinson and Company
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone
This trial is conducted in Asia. The aim of this trial is to compare the glycaemic control when subjects initiate a biphasic insulin aspart 30 treatment followed by an intensified treatment if treatment target of HbA1c below 7%…
- Trial name
- NCT01215435
- Testing
- biphasic insulin aspart 30
- Where
- Iran
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner
The purpose of this study is to evaluate EndoBarrier Gastrointestinal Liner in the post marketing environment in subjects who are obese and have Type 2 Diabetes.
- Trial name
- NCT01114438
- Testing
- EndoBarrier Gastrointestinal Liner
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Morphic Medical Inc.
Type 2 Diabetes
Home-based Diabetes-Modified Behavioral Activation Treatment for Low Income Seniors With T2DM
The objective of this protocol is to evaluate the efficacy and cost-effectiveness of 8 sessions of in-home, telephone-delivered, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT)…
- Trial name
- HOME DM-BAT (NCT04203147)
- Testing
- Supportive Therapy (Control), Home DM-BAT
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- State University of New York at Buffalo
Type 2 Diabetes Mellitus, Bone Remodeling
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
The purpose of this study is to determine changes in bone turnover markers and calcitonin following the initiation of exenatide compared to placebo in postmenopausal women wtih type 2 diabetes.
- Trial name
- CMBD (NCT01381926)
- Testing
- exenatide, Saline
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.